{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:21:49Z","timestamp":1793830909879,"version":"4.6.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T00:00:00Z","timestamp":1615593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.esmoop.2021.100098","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T06:36:58Z","timestamp":1617345418000},"page":"100098","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7613-8354","authenticated-orcid":false,"given":"H.","family":"El Hajj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vanseymortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bogart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Abdeddaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Leblanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Le Deley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Narducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.esmoop.2021.100098_bib1","first-page":"284","article-title":"Ovarian cancer statistics, 2018: ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100098_bib2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2014.56.3106","article-title":"Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182","volume":"33","author":"Horowitz","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100098_bib3","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3390\/cancers12030768","article-title":"30 years of experience in the management of stage III and IV epithelial ovarian cancer: impact of surgical strategies on survival","volume":"12","author":"Delga","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.esmoop.2021.100098_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2017.10.030","article-title":"No improvement in long-term survival for epithelial ovarian cancer patients: a population-based study between 1989 and 2014 in the Netherlands","volume":"88","author":"Timmermans","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2021.100098_bib5","first-page":"497429","article-title":"Treatment for recurrent ovarian cancer\u2014at first relapse","volume":"2010","author":"Ushijima","year":"2010","journal-title":"J\u00a0Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100098_bib6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.esmoop.2021.100098_bib7","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100098_bib8","first-page":"319","article-title":"Clinical results of cytoreduction and HIPEC in pseudomyxoma peritonei","volume":"134","author":"Lutton","year":"2007","journal-title":"Cancer Treat Res"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100098_bib9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/02656736.2017.1310938","article-title":"Pseudomyxoma peritonei: natural history and treatment","volume":"33","author":"Mittal","year":"2017","journal-title":"Int J Hyperthermia"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100098_bib10","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis","volume":"22","author":"Helm","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100098_bib11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study","volume":"28","author":"Elias","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100098_bib12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.esmoop.2021.100098_bib15","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.esmoop.2021.100098_bib16","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1016\/j.ejca.2013.08.002","article-title":"Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer","volume":"49","author":"Gonzalez-Martin","year":"2013","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100098_bib17","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100098_bib18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/IGC.0000000000000836","article-title":"Efficacy and safety of bevacizumab-containing therapy in newly diagnosed ovarian cancer","volume":"27","author":"Oza","year":"2017","journal-title":"Int J Gynecol Cancer"},{"issue":"25","key":"10.1016\/j.esmoop.2021.100098_bib19","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100098_bib20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"16","key":"10.1016\/j.esmoop.2021.100098_bib21","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2014.56.7974","article-title":"Statistical challenges in the analysis of health-related quality of life in cancer clinical trials","volume":"34","author":"Bonnetain","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100098_bib22","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2016.01.008","article-title":"Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center","volume":"140","author":"Mueller","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100098_bib23","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ygyno.2016.12.017","article-title":"Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer","volume":"144","author":"Kessous","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100098_bib24","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/IGC.0b013e31826a3559","article-title":"Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, Fallopian, and peritoneal cancer in day-to-day practice: a retrospective French multicentric study","volume":"22","author":"Luyckx","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"7353","key":"10.1016\/j.esmoop.2021.100098_bib25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100098_bib26","first-page":"517","article-title":"Prognostically relevant gene signatures of high-grade serous ovarian carcinoma","volume":"123","author":"Verhaak","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"10","key":"10.1016\/j.esmoop.2021.100098_bib27","doi-asserted-by":"crossref","first-page":"dju249","DOI":"10.1093\/jnci\/dju249","article-title":"Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer","volume":"106","author":"Konecny","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100098_bib28","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/path.4536","article-title":"Efficient molecular subtype classification of high-grade serous ovarian cancer: molecular subtype classification of ovarian cancer","volume":"236","author":"Leong","year":"2015","journal-title":"J\u00a0Pathol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100098_bib29","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/00015458.2004.11679577","article-title":"Rationale for hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment or prevention of peritoneal carcinomatosis","volume":"104","author":"Detroz","year":"2004","journal-title":"Acta Chir Belg"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100098_bib30","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1245\/s10434-007-9792-y","article-title":"Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study","volume":"15","author":"de Bree","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"S24","key":"10.1016\/j.esmoop.2021.100098_bib31","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1002\/cncr.32505","article-title":"Hyperthermic intraperitoneal chemotherapy for ovarian cancer: the heat is on","volume":"125","author":"Koole","year":"2019","journal-title":"Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921000557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921000557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:24:43Z","timestamp":1761855883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921000557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2059702921000557"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100098","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100098"}}